Post-pandemic Era Global Multivalent Vaccines Market Segment Research Report 2024
Summary
The global economy is expected to expand 5.6% in 2021，global recovery is strong but uneven as many emerging market and developing economies continue to struggle with the COVID-19 pandemic, the world is unlikely to ever reach global herd immunity. However, the recovery in many countries is being held back by a resurgence of COVID-19 cases and lagging vaccination progress, as well as the withdrawal of policy support in some instances.
The annual U.S. economic growth rate slipped to -3.5% in 2020, but grew at a yearly pace of more than 6% in the previous two quarters of 2021. The economy of continental Europe bounced back in the second quarter after having contracted in both the fourth quarter of 2020 and the first quarter of 2021, as the vaccinations accelerated, and governments eased restrictions. Among major economies, the annualized growth rate was 6.1% in Germany, 3.6% in France, 11.2% in Italy, and 11.7% in Spain. The especially rapid growth in Spain and Italy was attributed to a surge in consumer spending, likely the result of an easing of economic restrictions.
Regional Economic ProspectsGrowth in the East Asia and Pacific is projected to accelerate by 7.7% in 2021, Central Asia is forecast to grow by 3.9% this year, economic activity in the Middle East and North Africa is forecast to advance by 2.4%, South Asia is projected to expand by 6.8%.
The global Multivalent Vaccines market size was USD XX billion in 2021. It is likely to progress at a CAGR of XX% during the forecast period of 2022-2027, according to MR Accuracy Reports analysis, The segment in Multivalent Vaccines market is estimated to reach a market value of USD XX billion by 2021 from an initial market value of USD XX billion in 2021. China market value in 2021 is about USD XX billion, and China Multivalent Vaccines production is XX (K Units). US market value in 2021 is about USD XX billion, and US Multivalent Vaccines production is XX (K Units). Europe market value in 2021 is about USD XX billion, and Europe Multivalent Vaccines production is XX (K Units).
Regional Segmentation (Value; Revenue, USD Million, 2017 - 2027) of Multivalent Vaccines Market by MR Accuracy Reports Include
USA
Europe
China
Japan
India
Korea
Southeast Asia
Competitive Analysis; Who are the Major Players in Multivalent Vaccines Market?
GlaxoSmithKline, plc (U.K.)
Pfizer, Inc. (U.S.)
Merck & Co., Inc. (U.S.)
Sanofi Pasteur SA (France)
Astellas Pharma Inc. (Japan)
CSL Limited (Australia)
Emergent BioSolutions, Inc. (U.S.)
Johnson & Johnson (U.S.)
MedImmune, LLC (U.S.)
Serum Institute of India Pvt. Ltd. (India)
Bavarian Nordic (Denmark)
Mitsubishi Tanabe Pharma Corporation (Japan)
Daiichi Sankyo (Japan)
Protein Sciences Corporation (U.S.)
Panacea Biotec (India)
Major Type of Multivalent Vaccines Covered in MR Accuracy Reports report
Conjugate Vaccines
Inactivated and Subunit Vaccines
Live Attenuated Vaccines
Toxoid Vaccines
Recombinant Vaccines
Application Segments Covered in MR Accuracy Reports Market
Pediatrics
Adults
For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Content
Table of Contents
Global Multivalent Vaccines Market Segment Research Report 2021
1. Research Scope
2. Market Overview
2.1 Product Introduction, Application, Picture
2.2 Global Multivalent Vaccines Market by Value
2.2.1 Global Multivalent Vaccines Revenue by Type
2.2.2 Global Multivalent Vaccines Market by Value (%)
2.3 Global Multivalent Vaccines Market by Production
2.3.1 Global Multivalent Vaccines Production by Type
2.3.2 Global Multivalent Vaccines Market by Production (%)
3. The Major Driver of Multivalent Vaccines Industry
3.1 Historical & Forecast Global Multivalent Vaccines Demand
3.2 Largest Application for Multivalent Vaccines (2017-2027)
3.3 The Major Downstream Company in China Market 2021
4. Global and Regional Multivalent Vaccines Market
4.1 Regional Market Size in Terms of Production & Demand (2021)
4.2 Regional Market Share in Terms of Revenue (2019-2027)
4.3 Concentration Ratio (CR5& CR10) of Multivalent Vaccines Market
4.4 Mergers & Acquisitions, Expansion Plans
5. US Multivalent Vaccines Production, Demand (2017-2027)
5.1 Current and Estimated Production Breakdown by Type
5.2 Current and Estimated Demand Breakdown by Type
5.3 Current and Estimated Demand Breakdown by Application
5.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
5.5 Current and Estimated Revenue Breakdown by Application (2017-2027)
6. Europe Multivalent Vaccines Production, Demand (2017-2027)
6.1 Current and Estimated Production Breakdown by Type
6.2 Current and Estimated Demand Breakdown by Type
6.3 Current and Estimated Demand Breakdown by Application
6.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
6.5 Current and Estimated Revenue Breakdown by Application (2017-2027)
7. China Multivalent Vaccines Production, Demand (2017-2027)
7.1 Current and Estimated Production Breakdown by Type
7.2 Current and Estimated Demand Breakdown by Type
7.3 Current and Estimated Demand Breakdown by Application
7.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
7.5 Current and Estimated Revenue Breakdown by Application (2017-2027)
8. Japan Multivalent Vaccines Production, Demand (2017-2027)
8.1 Current and Estimated Production Breakdown by Type
8.2 Current and Estimated Demand Breakdown by Type
8.3 Current and Estimated Demand Breakdown by Application
8.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
8.5 Current and Estimated Revenue Breakdown by Application (2017-2027)
9. India Multivalent Vaccines Production, Demand (2017-2027)
9.1 Current and Estimated Production Breakdown by Type
9.2 Current and Estimated Demand Breakdown by Type
9.3 Current and Estimated Demand Breakdown by Application
9.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
9.5 Current and Estimated Revenue Breakdown by Application (2017-2027)
10. Korea Multivalent Vaccines Production, Demand (2017-2027)
10.1 Current and Estimated Production Breakdown by Type
10.2 Current and Estimated Demand Breakdown by Type
10.3 Current and Estimated Demand Breakdown by Application
10.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
10.5 Current and Estimated Revenue Breakdown by Application (2017-2027)
11. Southeast Asia Multivalent Vaccines Production, Demand (2017-2027)
11.1 Current and Estimated Production Breakdown by Type
11.2 Current and Estimated Demand Breakdown by Type
11.3 Current and Estimated Demand Breakdown by Application
11.4 Current and Estimated Revenue Breakdown by Type (2017-2027)
11.5 Current and Estimated Revenue Breakdown by Application (2017-2027)
12. Global Multivalent Vaccines Average Price Trend
12.1 Market Price for Each Type of Multivalent Vaccines in US (2017-2021)
12.2 Market Price for Each Type of Multivalent Vaccines in Europe (2017-2021)
12.3 Market Price for Each Type of Multivalent Vaccines in China (2017-2021)
12.4 Market Price for Each Type of Multivalent Vaccines in Japan (2017-2021)
12.5 Market Price for Each Type of Multivalent Vaccines in India (2017-2021)
12.6 Market Price for Each Type of Multivalent Vaccines in Korea (2017-2021)
12.7 Market Price for Each Type of Multivalent Vaccines in Southeast Asia (2017-2021)
13. Industrial Chain (Impact of COVID-19)
13.1 Multivalent Vaccines Industrial Chain Analysis
13.2 Downstream
13.3 Impact of COVID-19
13.4 Technology Trends of Multivalent Vaccines
14. Multivalent Vaccines Competitive Landscape
14.1 GlaxoSmithKline, plc (U.K.)
14.1.1 GlaxoSmithKline, plc (U.K.) Company Profiles
14.1.2 GlaxoSmithKline, plc (U.K.) Product Introduction
14.1.3 GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Sales, Revenue (2017-2021)
14.1.4 Strategic initiatives
14.2 Pfizer, Inc. (U.S.)
14.2.1 Pfizer, Inc. (U.S.) Company Profiles
14.2.2 Pfizer, Inc. (U.S.) Product Introduction
14.2.3 Pfizer, Inc. (U.S.) Multivalent Vaccines Sales, Revenue (2017-2021)
14.2.4 Strategic initiatives
14.3 Merck & Co., Inc. (U.S.)
14.3.1 Merck & Co., Inc. (U.S.) Company Profiles
14.3.2 Merck & Co., Inc. (U.S.) Product Introduction
14.3.3 Merck & Co., Inc. (U.S.) Multivalent Vaccines Sales, Revenue (2017-2021)
14.3.4 Strategic initiatives
14.4 Sanofi Pasteur SA (France)
14.4.1 Sanofi Pasteur SA (France) Company Profiles
14.4.2 Sanofi Pasteur SA (France) Product Introduction
14.4.3 Sanofi Pasteur SA (France) Multivalent Vaccines Sales, Revenue (2017-2021)
14.4.4 Strategic initiatives
14.5 Astellas Pharma Inc. (Japan)
14.5.1 Astellas Pharma Inc. (Japan) Company Profiles
14.5.2 Astellas Pharma Inc. (Japan) Product Introduction
14.5.3 Astellas Pharma Inc. (Japan) Multivalent Vaccines Sales, Revenue (2017-2021)
14.5.4 Strategic initiatives
14.6 CSL Limited (Australia)
14.6.1 CSL Limited (Australia) Company Profiles
14.6.2 CSL Limited (Australia) Product Introduction
14.6.3 CSL Limited (Australia) Multivalent Vaccines Sales, Revenue (2017-2021)
14.6.4 Strategic initiatives
14.7 Emergent BioSolutions, Inc. (U.S.)
14.7.1 Emergent BioSolutions, Inc. (U.S.) Company Profiles
14.7.2 Emergent BioSolutions, Inc. (U.S.) Product Introduction
14.7.3 Emergent BioSolutions, Inc. (U.S.) Multivalent Vaccines Sales, Revenue (2017-2021)
14.7.4 Strategic initiatives
14.8 Johnson & Johnson (U.S.)
14.8.1 Johnson & Johnson (U.S.) Company Profiles
14.8.2 Johnson & Johnson (U.S.) Product Introduction
14.8.3 Johnson & Johnson (U.S.) Multivalent Vaccines Sales, Revenue (2017-2021)
14.8.4 Strategic initiatives
14.9 MedImmune, LLC (U.S.)
14.9.1 MedImmune, LLC (U.S.) Company Profiles
14.9.2 MedImmune, LLC (U.S.) Product Introduction
14.9.3 MedImmune, LLC (U.S.) Multivalent Vaccines Sales, Revenue (2017-2021)
14.9.4 Strategic initiatives
14.10 Serum Institute of India Pvt. Ltd. (India)
14.10.1 Serum Institute of India Pvt. Ltd. (India) Company Profiles
14.10.2 Serum Institute of India Pvt. Ltd. (India) Product Introduction
14.10.3 Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Sales, Revenue (2017-2021)
14.10.4 Strategic initiatives
14.11 Bavarian Nordic (Denmark)
14.12 Mitsubishi Tanabe Pharma Corporation (Japan)
14.13 Daiichi Sankyo (Japan)
14.14 Protein Sciences Corporation (U.S.)
14.15 Panacea Biotec (India)
15. Conclusion
List of Figure
List of Tables and Figures
Figure 1. Total Demand by Application of Multivalent Vaccines Industry (Volume)
Figure 2. Multivalent Vaccines Production & Demand by Regions in 2021
Figure 3. Regional Market Share in Terms of Revenue (2021&2027)
Figure 4. The Top 10 and 5 Players Market Share by Multivalent Vaccines Revenue in 2021
Figure 5. US Multivalent Vaccines Production, Demand (2017-2027)
Figure 6. Production Breakdown by Type (%)
Figure 7. Demand Breakdown by Type (%)
Figure 8. Demand Breakdown by Application (%)
Figure 9. Revenue Breakdown by Type (%)
Figure 10. Revenue Breakdown by Application (%)
Figure 11. Europe Multivalent Vaccines Production, Demand (2017-2027)
Figure 12. Production Breakdown by Type (%)
Figure 13. Demand Breakdown by Type (%)
Figure 14. Demand Breakdown by Application (%)
Figure 15. Revenue Breakdown by Type (%)
Figure 16. Revenue Breakdown by Application (%)
Figure 17. China Multivalent Vaccines Production, Demand (2017-2027)
Figure 18. Production Breakdown by Type (%)
Figure 19. Demand Breakdown by Type (%)
Figure 20. Demand Breakdown by Application (%)
Figure 21. Current and Estimated Revenue Breakdown by Type
Figure 22. Revenue Breakdown by Type (%)
Figure 23. Revenue Breakdown by Application (%)
Figure 24. Japan Multivalent Vaccines Production, Demand (2017-2027)
Figure 25. Production Breakdown by Type (%)
Figure 26. Demand Breakdown by Type (%)
Figure 27. Demand Breakdown by Application (%)
Figure 28. Revenue Breakdown by Type (%)
Figure 29. Revenue Breakdown by Application (%)
Figure 30. India Multivalent Vaccines Production, Demand (2017-2027)
Figure 31. Production Breakdown by Type (%)
Figure 32. Demand Breakdown by Type (%)
Figure 33. Demand Breakdown by Application (%)
Figure 34. Revenue Breakdown by Type (%)
Figure 35. Revenue Breakdown by Application (%)
Figure 36. Korea Multivalent Vaccines Production, Demand (2017-2027)
Figure 37. Production Breakdown by Type (%)
Figure 38. Demand Breakdown by Type (%)
Figure 39. Demand Breakdown by Application (%)
Figure 40. Revenue Breakdown by Type (%)
Figure 41. Revenue Breakdown by Application (%)
Figure 42. Southeast Asia Multivalent Vaccines Production, Demand (2017-2027)
Figure 43. Current and Estimated Production Breakdown by Type (2017-2027)
Figure 44. Production Breakdown by Type (%)
Figure 45. Demand Breakdown by Type (%)
Figure 46. Revenue Breakdown by Type (%)
Figure 47. Revenue Breakdown by Application (%)
Figure 48. Industrial Chain
Table 1. Top Manufacturers and Market Segmentation
Table 2. Product Introduction, Application, Picture
Table 3. Multivalent Vaccines Revenue, by Type (Million USD) (2017-2027)
Table 4. Multivalent Vaccines Production, by Type (K Unit) (2017-2027)
Table 5. Multivalent Vaccines Demand (K Unit) by Application (2017-2027)
Table 6. Multivalent Vaccines Demand (Million USD) by Application (2017-2027)
Table 7. The Major Downstream Company in China
Table 8. Regional Market Share in Terms of Production & Demand (2021)
Table 9. Regional Market Share in Terms of Revenue (2021&2027)
Table 10. Ranking of Global Top Multivalent Vaccines Companies by Revenue, Concentration Ratio in 2021
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. US Multivalent Vaccines Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
Table 13. Current and Estimated Production Breakdown by Type (2017-2027)
Table 14. Current and Estimated Demand Breakdown by Type (2017-2027)
Table 15. Current and Estimated Demand Breakdown by Application (2017-2027)
Table 16. Current and Estimated Revenue Breakdown by Type
Table 17. Current and Estimated Revenue Breakdown by Application
Table 18. Europe Multivalent Vaccines Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
Table 19. Current and Estimated Production Breakdown by Type (2017-2027)
Table 20. Current and Estimated Demand Breakdown by Type (2017-2027)
Table 21. Current and Estimated Demand Breakdown by Application (2017-2027)
Table 22. Current and Estimated Revenue Breakdown by Type
Table 23. Current and Estimated Revenue Breakdown by Application
Table 24. China Multivalent Vaccines Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
Table 25. Table Current and Estimated Production Breakdown by Type
Table 26. Current and Estimated Demand Breakdown by Type
Table 27. Current and Estimated Demand Breakdown by Application
Table 28. Current and Estimated Revenue Breakdown by Application
Table 29. Japan Multivalent Vaccines Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
Table 30. Current and Estimated Production Breakdown by Type (2017-2027)
Table 31. Current and Estimated Demand Breakdown by Type (2017-2027)
Table 32. Current and Estimated Demand Breakdown by Application (2017-2027)
Table 33. Current and Estimated Revenue Breakdown by Type
Table 34. Current and Estimated Revenue Breakdown by Application
Table 35. India Multivalent Vaccines Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
Table 36. Current and Estimated Production Breakdown by Type (2017-2027)
Table 37. Current and Estimated Demand Breakdown by Type (2017-2027)
Table 38. Current and Estimated Demand Breakdown by Application (2017-2027)
Table 39. Current and Estimated Revenue Breakdown by Type
Table 40. Current and Estimated Revenue Breakdown by Application
Table 41. Korea Multivalent Vaccines Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
Table 42. Current and Estimated Production Breakdown by Type (2017-2027)
Table 43. Current and Estimated Demand Breakdown by Type (2017-2027)
Table 44. Current and Estimated Demand Breakdown by Application (2017-2027)
Table 45. Current and Estimated Revenue Breakdown by Type
Table 46. Current and Estimated Revenue Breakdown by Application
Table 47. Southeast Asia Multivalent Vaccines Production (K Unit), Market Revenue (Million USD), Demand (K Unit) (2017-2027)
Table 48. Table Current and Estimated Demand Breakdown by Type (2017-2027)
Table 49. Current and Estimated Demand Breakdown by Application (2017-2027)
Table 50. Current and Estimated Revenue Breakdown by Type
Table 51. Current and Estimated Revenue Breakdown by Application
Table 52. Market Price (USD/Unit) for Each Type of Multivalent Vaccines in US (2017-2021)
Table 53. Market Price (USD/Unit) for Each Type of Multivalent Vaccines in Europe (2017-2021)
Table 54. Market Price (USD/Unit) for Each Type of Multivalent Vaccines in China (2017-2021)
Table 55. Market Price (USD/Unit) for Each Type of Multivalent Vaccines in Japan (2017-2021)
Table 56. Market Price (USD/Unit) for Each Type of Multivalent Vaccines in India (2017-2021)
Table 57. Market Price (USD/Unit) for Each Type of Multivalent Vaccines in Korea (2017-2021)
Table 58. Market Price (USD/Unit) for Each Type of Multivalent Vaccines in Southeast Asia (2017-2021)
Table 59. Key Downstream Customer in Each Application Field
Table 60. GlaxoSmithKline, plc (U.K.) Profiles
Table 61. GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Product Introduction
Table 62. GlaxoSmithKline, plc (U.K.) Multivalent Vaccines Sales (Unit), Revenue (Million USD) (2017-2021)
Table 63. GlaxoSmithKline, plc (U.K.) Strategic initiatives
Table 64. Pfizer, Inc. (U.S.) Profiles
Table 65. Pfizer, Inc. (U.S.) Multivalent Vaccines Product Introduction
Table 66. Pfizer, Inc. (U.S.) Multivalent Vaccines Sales (Unit), Revenue (Million USD) (2017-2021)
Table 67. Pfizer, Inc. (U.S.) Strategic initiatives
Table 68. Merck & Co., Inc. (U.S.) Profiles
Table 69. Merck & Co., Inc. (U.S.) Multivalent Vaccines Product Introduction
Table 70. Merck & Co., Inc. (U.S.) Multivalent Vaccines Sales (Unit), Revenue (Million USD) (2017-2021)
Table 71. Merck & Co., Inc. (U.S.) Strategic initiatives
Table 72. Sanofi Pasteur SA (France) Profiles
Table 73. Sanofi Pasteur SA (France) Multivalent Vaccines Product Introduction
Table 74. Sanofi Pasteur SA (France) Multivalent Vaccines Sales (Unit), Revenue (Million USD) (2017-2021)
Table 75. Sanofi Pasteur SA (France) Strategic initiatives
Table 76. Astellas Pharma Inc. (Japan) Profiles
Table 77. Astellas Pharma Inc. (Japan) Multivalent Vaccines Product Introduction
Table 78. Astellas Pharma Inc. (Japan) Multivalent Vaccines Sales (Unit), Revenue (Million USD) (2017-2021)
Table 79. Astellas Pharma Inc. (Japan) Strategic initiatives
Table 80. CSL Limited (Australia) Profiles
Table 81. CSL Limited (Australia) Multivalent Vaccines Product Introduction
Table 82. CSL Limited (Australia) Multivalent Vaccines Sales (Unit), Revenue (Million USD) (2017-2021)
Table 83. CSL Limited (Australia) Strategic initiatives
Table 84. Emergent BioSolutions, Inc. (U.S.) Profiles
Table 85. Emergent BioSolutions, Inc. (U.S.) Multivalent Vaccines Product Introduction
Table 86. Emergent BioSolutions, Inc. (U.S.) Multivalent Vaccines Sales (Unit), Revenue (Million USD) (2017-2021)
Table 87. Emergent BioSolutions, Inc. (U.S.) Strategic initiatives
Table 88. Johnson & Johnson (U.S.) Profiles
Table 89. Johnson & Johnson (U.S.) Multivalent Vaccines Product Introduction
Table 90. Johnson & Johnson (U.S.) Multivalent Vaccines Sales (Unit), Revenue (Million USD) (2017-2021)
Table 91. Johnson & Johnson (U.S.) Strategic initiatives
Table 92. MedImmune, LLC (U.S.) Profiles
Table 93. MedImmune, LLC (U.S.) Multivalent Vaccines Product Introduction
Table 94. MedImmune, LLC (U.S.) Multivalent Vaccines Sales (Unit), Revenue (Million USD) (2017-2021)
Table 95. MedImmune, LLC (U.S.) Strategic initiatives
Table 97. Serum Institute of India Pvt. Ltd. (India) Profiles
Table 98. Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Product Introduction
Table 99. Serum Institute of India Pvt. Ltd. (India) Multivalent Vaccines Sales (Unit), Revenue (Million USD) (2017-2021)
Table 100. Serum Institute of India Pvt. Ltd. (India) Strategic initiatives
Table 101. Bavarian Nordic (Denmark) Profiles
Table 102. Bavarian Nordic (Denmark) Multivalent Vaccines Product Introduction
Table 103. Bavarian Nordic (Denmark) Multivalent Vaccines Sales (Unit), Revenue (Million USD) (2017-2021)
Table 104. Bavarian Nordic (Denmark) Strategic initiatives
Table 105. Mitsubishi Tanabe Pharma Corporation (Japan) Profiles
Table 106. Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Product Introduction
Table 107. Mitsubishi Tanabe Pharma Corporation (Japan) Multivalent Vaccines Sales (Unit), Revenue (Million USD) (2017-2021)
Table 108. Mitsubishi Tanabe Pharma Corporation (Japan) Strategic initiatives
Table 109. Daiichi Sankyo (Japan) Profiles
Table 110. Daiichi Sankyo (Japan) Multivalent Vaccines Product Introduction
Table 111. Daiichi Sankyo (Japan) Multivalent Vaccines Sales (Unit), Revenue (Million USD) (2017-2021)
Table 112. Daiichi Sankyo (Japan) Strategic initiatives
Table 113. Protein Sciences Corporation (U.S.) Profiles
Table 114. Protein Sciences Corporation (U.S.) Multivalent Vaccines Product Introduction
Table 115. Protein Sciences Corporation (U.S.) Multivalent Vaccines Sales (Unit), Revenue (Million USD) (2017-2021)
Table 116. Protein Sciences Corporation (U.S.) Strategic initiatives
Table 117. Panacea Biotec (India) Profiles
Table 118. Panacea Biotec (India) Multivalent Vaccines Product Introduction
Table 119. Panacea Biotec (India) Multivalent Vaccines Sales (Unit), Revenue (Million USD) (2017-2021)
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices